OMAR RABAB'H

Dr. OMAR RABAB'H

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2021 in Neurology International
Verified
Journal Article
Open access
PDF file
AAali al-ramadan
ali al-ramadan
OROMAR RABAB'H
OMAR RABAB'H
JSJawad Shah
Jawad Shah
AGAbeer Gharaibeh
Abeer Gharaibeh
Coronavirus disease 2019 (COVID-19) is an emerging global health emergency caused by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The global outbreak of SARS-CoV-2 infection has been declared a global pandemic by the World Health Organization (WHO). The clinical presentation of SARS-CoV-2 infection depends on the severity of the disease and may range from an asymptomatic infection to a severe and lethal illness. Fever, cough, and shortness of breath are among the most common symptoms associated with SARS-CoV-2 infection. Accumulating evidence indicates that COVID-19 patients commonly develop neurological symptoms, such as headache, altered mental status, anosmia, and myalgia. In this comprehensive literature review, we have summarized the most common neurological complications and reported neurological case studies associated with COVID-19, and neurological side effects associated with COVID-19 treatments. Additionally, the post-acute COVID-19 syndrome and long-term neurological complications were discussed. We also explained the proposed mechanisms that are involved in the pathogenesis of these neurological complications.

30 June 2021 in Cureus
Verified
Journal Article
Open access
OROMAR RABAB'H
OMAR RABAB'H
AAAli Al-Ramadan
Ali Al-Ramadan
JSJawad Shah
Jawad Shah
HLHugo Lopez-Negrete
Hugo Lopez-Negrete
AGAbeer Gharaibeh
Abeer Gharaibeh
Glioblastoma multiforme (GBM) is an aggressive tumor that has a poor prognosis with a median survival of 15 months with treatment and 3-4 months without treatment. Subsets of patients are found to survive longer than two years, some survivors lived more than 10 years, and rare cases survived 20 years or more with treatment. Better prognosis has been found to be associated with many factors. Some of these factors are related to patients' characteristics, biological factors that impact tumor aggressiveness, and/or factors associated with treatment. However, the exact contribution for extended survival is still not known. Finding the factors that have a strong impact on the long survival is of high importance and can help give hope to better treat glioblastoma cases. In this report, we present a case of a glioblastoma patient who was diagnosed at the age of 47 years with more than 20-year survival. We further discuss the suggested factors that may have contributed to a better prognosis with a focus on the possible role of varicella-zoster infection in mediating long-term survival.

1 August 2021 in Cancers
Verified
Journal Article
Open access
PDF file
OROMAR RABAB'H
OMAR RABAB'H
AGAbeer Gharaibeh
Abeer Gharaibeh
AAali al-ramadan
ali al-ramadan
MIManar Ismail
Manar Ismail
JSJawad Shah
Jawad Shah
Neurofibromatosis type 1 is an autosomal dominant genetic disease and a common tumor predisposition syndrome that affects 1 in 3000 to 4000 patients in the USA. Although studies have been conducted to better understand and manage this disease, the underlying pathogenesis of neurofibromatosis type 1 has not been completely elucidated, and this disease is still associated with significant morbidity and mortality. Treatment options are limited to surgery with chemotherapy for tumors in cases of malignant transformation. In this review, we summarize the advances in the development of targeted pharmacological interventions for neurofibromatosis type 1 and related conditions.

24 April 2026 in Circulation Research
Verified
Journal Article
Closed access
CCColin J. Clark
Colin J. Clark
CAChristian E. Anderson
Christian E. Anderson
ADAlex Dou
Alex Dou
JDJason M. Dierdorff
Jason M. Dierdorff
JGJason D. Galpin
Jason D. Galpin
CAChristopher A. Ahern
Christopher A. Ahern
BACKGROUND: Na V (voltage-gated sodium) channels drive cardiac excitability. Although Na V 1.5 is the primary cardiac isoform, the composition and functional contributions of non-Na V 1.5 isoforms in the heart remain unclear. METHODS: Here, we developed a chemical-genetic mouse model (Na V 1.5 GX/GX ) in which Na V 1.5 can be selectively and reversibly inhibited by acyl- and aryl-sulfonamide compounds (GX [acyl- and aryl-sulfonamide compounds typically denoted by the name GX-### and associated items] drugs). Cardiac activity was assessed by electrocardiograms in vivo, and optical mapping was used for imaging of ex vivo hearts. Whole-cell voltage-clamp in tandem with validated toxins and isoform-selective inhibitors were used to examine sodium current composition. RESULTS: Na V 1.5 GX/GX mice exhibited normal cardiac function at baseline, but acute GX drug administration caused profound conduction defects and arrhythmias. Whole-heart optical mapping revealed dose-dependent chamber-specific sensitivity to Na V 1.5 inhibition, with the right ventricle being the most sensitive, followed by the left ventricle, left atrium, and right atrium. Patch-clamp recordings of isolated cardiomyocytes with application of Na V isoform-selective inhibitors showed that Na V 1.5 contributed 93% of sodium current in the left ventricle, 79% in the right ventricle, and 78% in the atria. Non-Na V 1.5 isoforms were differentially enriched across chambers: Na V 1.8 in the left ventricle, Na V 1.1/1.3 in the right ventricle, and Na V 1.2/1.6/1.7 in the atria. CONCLUSIONS: These results reveal a surprising chamber-specific isoform landscape of cardiac sodium currents, which may underlie the right ventricular predominant phenotype of Brugada syndrome. These data highlight non-Na V 1.5 isoforms as potential mediators of chamber-specific cardiac pathologies and as pharmacological targets.

1 December 2020 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
EAEyad Altamimi
Eyad Altamimi
MKMariam Khanfar
Mariam Khanfar
OROMAR RABAB'H
OMAR RABAB'H
ZDZain Dardas
Zain Dardas
LSLuma Srour
Luma Srour
BABilal Azab
Bilal Azab
Purpose: Four consanguineous Jordanian families with affected members of unknown gastrointestinal related diseases were recruited to assess the utility and efficiency of whole exome sequencing (WES) in reaching the definitive diagnosis. Patients and Methods: Members from four consanguineous Jordanian families were recruited in this study. Laboratory and imaging tests were used for initial diagnosis, followed by performing WES to test all affected members for the detection of causative variants. Sanger sequencing was used for validation. Results: We had a 100% success rate identifying each case presented in this study. Conclusion: This is the first study applying a WES testing approach in the diagnosis of pediatric diseases in Jordan. Our results strongly suggest the need to implement WES as an evident diagnostic tool in the clinical setting, as it will subsequently allow for proper disease management and genetic counseling.